Replies to post #155412 on Biotech Values

[dav1234]

so FRX looks like a short

[dav1234]

PDL BioPharma (PDLI -5.3%) slips after Credit Suisse cut the shares to Neutral on valuation and lowers its price target from $6.50 to $6.00. The firm adds that PDLI lacks significant optionality as new products deliver a finite and relatively short revenue stream.

Dew, are you familiar with PDLI ?..decent divi

[DewDiligence]

FDA issues CRL for FRX’s Cariprazine antipsychotic:

http://finance.yahoo.com/news/forest-laboratories-gedeon-richter-receive-070000969.html

…the Agency indicated more information, including additional clinical trial data, would be needed.

FRX is developing Cariprazine with Hungary’s Gideon Richter.